Page last updated: 2024-11-07

pseudoisocytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pseudoisocytidine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124345
SCHEMBL ID713634
MeSH IDM0059590

Synonyms (21)

Synonym
57100-18-2
2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-pyrimidin-4-one
pseudoisocytidine
4-(1h)-pyrimidinone, 2-amino-5-.beta.-d-ribofuranosyl-
59464-15-2
nsc279852
2-amino-5-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrimidin-6-one
AKOS015919923
4(1h)-pyrimidinone, 2-amino-5-beta-d-ribofuranosyl-
tdh73l8xqd ,
psi-isocytidine
5-(beta-d-ribofuranosyl)isocytosine
unii-tdh73l8xqd
4(1h)-pyrimidinone, 2-amino-5-.beta.-d-ribofuranosyl-
5-(.beta.-d-ribofuranosyl)isocytosine
SCHEMBL713634
4(1h)-pyrimidinone,2-amino-5-b-d-ribofuranosyl-
DTXSID20205717
AKOS025396670
Q15632736
A869762

Research Excerpts

Overview

Pseudoisocytidine (psi ICyd) is a C-nucleoside with enhanced stability and resistance to enzymatic deamination.

ExcerptReferenceRelevance
"Pseudoisocytidine (psi ICyd) is a C-nucleoside with enhanced stability and resistance to enzymatic deamination when compared to 5-azacytidine and 1-beta-D-arabinofuranosylcytosine. "( Biochemical, pharmacological, and phase I clinical evaluation of pseudoisocytidine.
Burchenal, JH; Chou, TC; Philips, FS; Sternberg, SS; Tan, CT; Woodcock, TM; Young, CW, 1980
)
1.94

Pharmacokinetics

ExcerptReferenceRelevance
" NBMPR-P and other inhibitors of nucleoside transport may have therapeutic applications in manipulation of the pharmacokinetic behavior and toxicity of nucleoside drugs."( Modification by nitrobenzylthioinosine-5'-monophosphate of pseudoisocytidine pharmacokinetics in mice and rats through inhibition of membrane transport.
Chou, TC; Kolassa, N; Paterson, AR, 1983
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (70.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.87 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]